title: Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin.
abstract: OBJECTIVE
  Correct execution of prescribed dosing regimen(s) is essential for patients to benefit from lipid lowering treatments. The objective of this study was to estimate the effect of a pharmaceutical care program on the adherence of once-daily atorvastatin treatment in patients with elevated cholesterol levels.
  
  
  METHODS
  In both linguistic regions of Belgium, two districts were randomized between usual care and a supportive intervention program. Eligible patients included hyperlipemic subjects taking atorvastatin for at least 3 months. 'Adherence' was defined as the proportion of days during which the electronic device record showed that the patient had taken the daily dose. 'Persistence' quantifies how long the treatment is executed.
  
  
  RESULTS
  A total of 392 patients from 35 pharmacies were included in the intent-to-treat (ITT) analysis of the data (194 patients received intervention and 198 in the control group). The intervention resulted in a 6.5% increase in post-baseline adherence (p < 0.001) mainly driven by a 13% increase in persistence at 1 year (p = 0.002).
  
  
  CONCLUSIONS
  A supportive pharmaceutical care program consisting of review by patient and pharmacist of each patient's electronically compiled dosing history, plus educational reminders, improves patient adherence to the once-daily atorvastatin dosing regimen, mainly by extending persistence.
authors.affiliation: AARDEX Ltd., Rue des Cyclistes Frontière 24, Visé, Belgium.
authors.forename: Bernard
authors.initials: B
authors.lastname: Vrijens
authors.forename: Ann
authors.initials: A
authors.lastname: Belmans
authors.forename: Katelijne
authors.initials: K
authors.lastname: Matthys
authors.forename: Erik
authors.initials: E
authors.lastname: de Klerk
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Lesaffre
mesh_terms: D000069059:Atorvastatin; D001530:Belgium; D003157:Community Pharmacy Services; D004334:Drug Administration Schedule; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D016347:Medical Records Systems, Computerized; D008875:Middle Aged; D010349:Patient Compliance; D010353:Patient Education as Topic; D010595:Pharmacists; D011369:Professional-Patient Relations; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin